Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease
Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of an extended release
formulation of the drug galantamine using a rapid dose escalation regimen.
Phase:
Phase 3
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.